Unicycive Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. All right, I think we are ready to get started. Thanks everyone for joining us again for this year's Guggenheim Healthcare Innovation Conference, and to day two today. I am Vamil Divan, one of the biopharm analysts here at Guggenheim. Next up in this room, we have Unicycive Therapeutics, and with me I have Shalabh Gupta, the CEO of the company. Thanks for giving us your time and joining us again, Shalabh. Maybe just to kick things off for those who are less familiar with Unicycive, maybe just an overview of the company. Obviously exciting times, important event coming up in a few months, but just a background of the company, where we are right now, and then we will look forward from there.
Yeah. Thank you, Vamil, and thank you to Guggenheim for having us. By way of background, we are a clinical stage biopharma company based in California. We have a lead drug, which is oxylanthanum carbonate, indicated for treatment of hyperphosphatemia in patients who are on dialysis, currently waiting for PDUFA date from the FDA, which is March 25, 2027.
Okay, great. Maybe just talk about this market that you are looking to get into in March. How are patients currently managed? I know there are some other therapies that have been on the market for some time. How are they currently managed with the current agents, and then what is sort of the unmet need that you see in this space right now?
Chronic kidney disease, the last stage of chronic kidney disease is stage 5, which is also called end-stage kidney disease, ESKD, or ESRD, end-stage renal disease. When patients are on dialysis, 80% of these patients need something to manage their phosphate because the dialysis, we are talking hemodialysis primarily, does not take out the phosphate, and phosphate that is present has nowhere to go but combines with the calcium and causes many complications, two being cardiovascular risk, which is increase in mortality and morbidity from heart attack and other cardiovascular complications, and the second is the fractures, increased risk of fractures because again, calcium phosphate combined together get deposited in soft tissue and cause pain as well as fractures. Currently, there are six approved drugs for treatment of hyperphosphatemia.
With the six approved drugs over the last several years, the compliance or the ability to control phosphate has been limited. If you take a more relaxed version, which is 4.5 milligrams per deciliter as a target serum phosphate level, you find 44% of U.S. population has not been able to achieve that target serum phosphate level. If you take more stringent number, which is 5.5 milligrams per deciliter, other way around, you will get to 75%. So one way or the other, you find that patients are not able to achieve their target serum phosphate level, and that begs the question why.
Yeah. It all comes down to the problem that exists with the existing treatment.
I misspoke. The numbers will be 75% if you take more stringent.
Right. Yeah. Okay. Yeah. Right.
The limitations, maybe you can elaborate on that a little bit more.
Sure. What are the limitations of the current- Existing treatment require patients to either take a large number of pills.
You would argument patients taking 12 to 15 pills per day, or large-size pills. There are large-size pills that are available which are fewer in number, but the large-size pills then come with the baggage of having to chew the pills. The large-size pills require patients to chew the pills, and these pills taste horrible because they are metallic. No matter what we add onto to mask the taste, they taste still metallic, so people don't like to chew the pills, and that is where the compliance becomes a huge challenge.
Okay. That is where OLC comes in. Maybe you can- Sure talk to us a little bit about the value proposition that OLC would offer to these patients, and maybe before getting to talking a little bit about the data- Sure you have generation date- Sure and how this could differentiate from the current agents.
Oxylanthanum carbonate is a proprietary new chemical entity based out of lanthanum. It's dilanthanum dioxycarbonate, and it is a drug that allows patient to be able to take a drug which comes in the form of a small pill. In most recent trial that we ran in patients who are on dialysis, it's a single-arm study that showed roughly 69% patients were able to control their target serum phosphate level by taking one small-size pill, which is a 500 milligram pill. It looks very much similar to the size of a baby aspirin. The way this drug is given, this drug is given in a small pill, one pill with each meal to swallow. No need to chew, and it can be just taken with a simple water. The titration of these drugs are based on what the serum phosphate level is for any given patient.
Starting dose for a drug like ours would be 500 milligram three times a day and can be titrated up to 1,000 milligram three times a day.
Okay. Perfect. Then, you'd mentioned that you have PDUFA date coming up, so maybe you can just talk about the status there in terms of resubmission and kind of any- Sure I don't know if there's anything you can share in terms of interactions or Yeah what we should expect between now and then at least.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
